Welcome to our dedicated page for Biolargo news (Ticker: BLGO), a resource for investors and traders seeking the latest updates and insights on Biolargo stock.
Stay informed about developments from BioLargo, Inc., a cleantech and environmental technology company advancing solutions for PFAS water treatment, energy storage, medical devices, and consumer products. News coverage typically focuses on the company's technology milestones, commercial partnerships, regulatory approvals, and market expansion activities across its multiple business segments.
Water treatment announcements often detail advancements in the company's AEC technology for PFAS removal, including system installations, performance validations, and partnerships with municipal or industrial clients. Energy storage news covers progress in Cellinity battery development, joint venture discussions, pilot facility operations, and applications for grid-scale storage projects. Medical device updates track the development and distribution partnerships for Bioclynse and other infection control products targeting surgical and wound care markets.
Corporate news includes financial performance reports, stock exchange listing developments, patent grants and intellectual property milestones, strategic partnerships and licensing agreements, and management commentary on business segment performance. Consumer product announcements highlight retail distribution expansions, product line extensions, and market reception for the Pooph brand and other direct-to-consumer offerings.
Regulatory and compliance news may cover environmental regulations affecting target markets, EPA standards for PFAS treatment, product certifications and testing results, and industry studies validating the company's technologies. Given BioLargo's focus on emerging environmental challenges and evolving regulatory frameworks, news flow often reflects the intersection of environmental policy, technological innovation, and commercial deployment across water treatment, energy storage, and healthcare sectors.
BioLargo (OTCQX: BLGO) closed 2025 highlighting disciplined development and early-stage deployments across environmental, energy, and medical platforms. Key 2025 advances include an Aqueous Electrostatic Concentrator (AEC) install for PFAS removal at a Lake Stockholm, New Jersey municipal plant, progress toward public-private Cellinity battery factory collaborations, and Clyra Medical's first production run for ViaClyr with distributor Advanced Solution under contract.
Management expects potential meaningful commercial revenue from Clyra in 2026, continued validation from clinical KOLs, and alignment of BioLargo technologies with a large infrastructure investment cycle, while noting timing and execution remain uncertain.
BioLargo (OTCQX:BLGO) announced its subsidiary BioLargo Equipment Solutions & Technologies was featured in Chemical Engineering for its Aqueous Electrostatic Concentrator (AEC) PFAS treatment, described as producing "nearly zero waste" while removing long-, short-, and ultra-short-chain PFAS. The company also delivered an AEC system to the Lake Stockholm, New Jersey drinking water facility and is supporting provisioning, integration, and commissioning with the general contractor.
Company statements note the delivery is the final stage before the AEC goes live for the Lake Stockholm community and reference New Jersey settlements exceeding $2.5 billion that support PFAS cleanup efforts.
BioLargo (OTCQX: BLGO) will present at Noble Capital Markets' 21st Annual Emerging Growth Equity Conference (NobleCon 21) on December 3, 2025 at 10:30 AM Eastern in Boca Raton, FL.
President & CEO Dennis P. Calvert will address prior-year financial results and ongoing business developments. The conference features formal presentations, fireside chats, one-on-one meetings and networking with hundreds of public company executives and keynote speakers.
Investors can attend the in-person session at Presentation Room 4 or learn more about the conference at nobleconference.com and company technologies at biolargo.com.
BioLargo (OTCQX:BLGO) will host an investor webcast and conference call on Friday, November 14, 2025 at 1:30 PM PT / 4:30 PM ET to review results for the quarter ended September 30, 2025, discuss recent milestones, and hold a Q&A session.
Live access: register at the webcast page at least 15 minutes early. Teleconference numbers and participant code are provided for domestic and international callers. A replay is available through February 14, 2027, and the webcast replay plus presentation materials will be posted on BioLargo's Investor Relations page at www.biolargo.com/investor-relations.
BioLargo (OTCQX:BLGO) subsidiary Clyra Medical Technologies signed an exclusive stocking distribution agreement with Advanced Solution to distribute ViaCLYR™ nationwide in the United States.
ViaCLYR™ uses Clyra's proprietary Clyrasept™ copper-iodine complex, described as antimicrobial and shown to have safety, efficacy, biocompatibility, and cost-effectiveness in FDA-cleared applications. The product is scheduled for market launch in early 2026. The alliance pairs Clyra's technology with Advanced Solution's national distribution network and clinical training capabilities to accelerate adoption across healthcare providers.
BioLargo (OTCQX:BLGO) announced a breakthrough upgrade to its patented Aqueous Electrostatic Concentrator (AEC) that cuts energy use by more than 90% for large-scale PFAS treatment versus prior AEC generations. The company cites prior May 2025 data showing up to 80% total life-cycle cost savings versus carbon technologies and claims non-detect PFAS removal <1 ppt in drinking and brackish water.
Example: a 1,000 gpm municipal system could see monthly energy costs fall from ~$208,000 to ~$15,700 (>$2.3M annual savings at $0.15/kWh). An industrial test showed 88% energy reduction; waste is reported as 1/40,000th that of carbon systems. A first commercial installation in New Jersey is nearing operation.
BioLargo (OTCQX: BLGO) announced that its CEO presented at the LD Micro Main Event XIX on October 20, 2025 at the Hotel del Coronado in San Diego.
The presentation covered Cellinity battery cell technology, BioLargo’s role in the global AI infrastructure investment cycle, and a general corporate update. The company filed a Form 8-K on October 20, 2025 to provide the presentation materials, which are available online at the company’s SEC filings page: https://www.biolargo.com/sec-filings.
BioLargo (OTCQX:BLGO) invites professionals to the 16th Annual Sustain SoCal Energy Event on October 16, 2025 at The Cove at UCI Beall Applied Innovation in Irvine, CA.
The full-day conference, themed "Energy in Perspective," runs 9:00 AM–7:00 PM and features a keynote by David Hayes, discussions on nuclear energy, hydrogen, AI-driven residential engagement, local energy programs, and the 2025 Sustainability Awards.
BioLargo is a sponsor and speaker and will highlight its #Cellinity battery technology for grid-scale energy storage. Registration and event details are available on the Sustain SoCal event page.
FAQ
What is the current stock price of Biolargo (BLGO)?
What is the market cap of Biolargo (BLGO)?
